• Duke LawThe Federal Circuit Bar Association and Center for Innovation Policy at Duke Law will be hosting a program focusing on important patent law issues affecting the protection of cutting-edge technology.  The program, entitled "Are Patents Under Attack?" will take place from 8:00 am to 4:45 pm ET on April 6, 2018 at Duke University School of Law in Durham, NC.  The program will include sessions on the following topics:

    • Women in IP Breakfast
    • The Impact of Recent Section 101 Patent Eligibility Cases on U.S. Innovation
    • Hot Topics in PTAB Proceedings.
    • Moderated Discussion with The Honorable Todd M. Hughes, Judge, U.S. Court of Appeals for the Federal Circuit
    • Supreme Court Review of Federal Circuit Decisions
    • A View from the Bench
    • Diversity in Courts, Agencies, Corporations and Law Firms

    Additional information regarding the program can be found here.  The program is complimentary for FCBA members and students and $150 for non-members.  Those interested in registering for the conference can do so here.

  • BPLAThe Federal Circuit Bar Association and Boston Patent Law Association will be hosting a discussion about the evolution of the patent system and the biggest issues facing patent policy and litigation today.  The program, entitled "The Patent System: Transformative Times," will take place from 2:30 pm to 5:30 pm ET on April 9, 2018 at Northeastern University in Boston, MA.  The program will include sessions on the following topics:

    • Fireside Chat with Circuit Judge Alan Lourie, U.S. Court of Appeals for the Federal Circuit
    • In-House Counsel Panel: "Perspectives on Decision-Making and Strategy"
    • Fireside Chat with Chief Judge David Ruschke, U.S. Patent and Trademark Office

    Additional information regarding the program can be found here.  The program is complimentary for FCBA members, $145 for BLPA members, and $285 for non-members.  Those interested in registering for the conference can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Protecting Software as a Medical Device With Patents, Design Patents and Trade Secrets" on April 12, 2018 from 1:00 to 2:30 pm EDT.  Cory C. Bell, Elizabeth D. Ferrill, and Susan Y. Tull of Finnegan Henderson Farabow Garrett & Dunner will guide counsel for companies in the medical device industry on protecting software as a medical device (SaMD), and also discuss the new FDA rules regulating SaMD and how to leverage IP law to protect SaMD.  The webinar will review the following issues:

    • What are the hurdles for patent counsel to demonstrate a software-related claim is not abstract?
    • What factors should counsel consider when determining what type of IP protection to seek?
    • What guidance have the courts provided in recent decisions concerning patent eligibility for software-related inventions?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • By Andrew Williams

    USPTO SealPharmaceutical patent owners have been one of the more vocal groups decrying the creation and existence of inter partes reviews and other PTAB post-issuance proceedings.  And for good reason.  Congress enacted the Hatch-Waxman statute to create an abbreviated approval pathway for generic small molecule drugs.  In so doing, it crafted a fine balance between the interests of branded pharmaceutical NDA holders and generic drug-product manufacturers.  As part of this balance, Congress established a procedure by which ANDA filers could challenge the validity of patents that cover the drug product and methods of its use in district court without needing to launch at risk.  This included the creation of the Orange Book, which listed all such patents.  An ANDA filer wishing to challenge these patents files a Paragraph IV certification for each patent that it believes is not infringed, is invalid, or is unenforceable.  Technically, however, it is the filing of the ANDA that is the act of infringement regardless of whether the patent is Orange Book listed or not.  Nevertheless, with the introduction of IPRs and related proceedings, ANDA filers have a new mechanism to challenge the validity of these patents outside the carefully balanced patent-resolution scheme of the Hatch-Waxman statute.  Correspondingly, the new PTAB proceedings have the potential to shift the balance away from patent and NDA holders and towards generic drug manufacturers.

    Likely in response to these concerns, Chief Judge Ruschke announced the results of an Orange Book-listed Patent Study during his "Chat with the Chief" on March 13, 2018.  The meeting presentation slides can be found here.  During the chat, the Chief Judge also revealed the results of an expanded panel study, which we will analyze in a future post.  For the Orange Book study, the PTAB classified a petition as challenging an Orange Book-listed patent if, unsurprisingly, the patent was listed in the Orange Book when the petition was filed.  The data provided was through the end of the fiscal year 2017, which ended on September 31, 2017.  We will look at three of the questions asked by the Office in this study.

    What Are the Filing Trends for Petitions Challenging Orange Book-listed Patents?

    The PTAB has been releasing filing trends for the various technology centers since at least April, 2015.  For fiscal year 2015, Bio/Pharma patents from TC 1600 accounted for 9% of all petitions filed.  For fiscal year 2017, that number was 11%.  However, it is important to keep in mind that this is a relative number, and that the total number of Bio/Pharma petitions has risen every year (despite the relative number hovering around 10%).  The current study broke down the numbers in this technology center by whether it was an Orange Book-listed patent or a miscellaneous Bio/Pharma patent.  The results since September 16, 2012, and the results for fiscal year 2017 are reproduced below.

    Figure 1

    Figure 2
    The picture that emerges is that, overall, Orange Book-listed patents have accounted for about half of all Bio/Pharma petitions, but that this ratio has recently shifted away from such patents.  This could be due to the rise in the use of IPRs and other post-grant proceedings in the BPCIA context.  The Patent Office also included the actual number of petitions that fell into the Orange Book-listed category, and it appears that such petitions peaked in FY15, with the number of petitions filed in FY17 being about 2/3 of the numbers filed in FY16 (80 versus 127).

    How Does the Institution Rate on Petitions Challenging Orange Book-listed Patents Compare to Those of Other Technologies?

    The Patent Office highlighted the fact that the cumulative institution rate of Orange Book petitions was essentially the same as the cumulative overall rate (66% versus 68%).  Interestingly, the institution rate of the miscellaneous Bio/Pharma patents was 60%, lower than both.  Moreover, whereas it would have made the study more complicated, it would have been interesting to break out the institution rate number by whether the patents contained composition-of-matter claims or method-of-use claims.

    What Are the Outcomes of Challenges to Orange Book-listed Patents?

    When looking at the 82 total final written decisions for Orange Book-listed patents, the Office found that more than 50% retained all claims as patentable.  This is an extraordinary number, considering the number for all other technologies was 17%.  The charts are reproduced below:

    Figure 3
    Nevertheless, the number one "number" highlighted by the study was that 83% of all such petitions resulted in the patent being unchanged.  This is represented in the below reproduced graphic:

    Figure 4
    Touting this number seems suspect, however.  The Patent Office considered a patent as being unchanged when it survived final written decision, when the parties settled, when the case was dismissed, and when the case was not instituted in the first place.  In addition to the aforementioned success of such patents at the final written decision stage, there are unique factors intrinsic to Orange Book-listed patents that may help explain this number.  For example, Orange Book-listed patent holders may be more motivated to settle with parties in order to retain the listing (and thereby prevent the flood-gates of ANDA filers from opening).  In addition, many petitioners are not the first ANDA filers, and the NDA holder may have already settled with the first filer.  In such cases, there may be less of a barrier to settle with follow-on challengers.  Importantly, the patent holder in such situations may not consider a settlement a positive outcome.

    The other two conclusions reached by the study relate to the issue of serial petitions.  In general, the Office has been concerned about multiple petitioners filing against the same patent.  However, the problem seems more pronounced in the Orange Book context because of the potential for multiple ANDA filers for a particular drug product.  Nevertheless, the Office found that 80% of all challenged Orange Book-listed patents have only 1 or 2 petitions filed against it, as opposed to 87% for all challenged patents.  Moreover, 85% of all challenged Orange Book-listed patents have 1 or 2 petitioners, as opposed to 94% for all challenged patents.  These numbers are presented in such a way to suggest that the problem is not as significant as feared.  However, what isn't represented is that 1/3 of all Orange Book-listed patents are challenged by more than one petitioner (as compared to 15.6% for all challenged patents).  Moreover, according to this study, 1/3 of all patents are challenged by more than one petition, but for Orange Book-listed patents, the number is closer to 42%.  Therefore, there does seem to be a multiple-petition or multiple-petitioner problem with this subset of patents.

    In any event, this study by the Patent Office is certainly interesting.  It does go a long way to allaying the fears of NDA holders.  Nevertheless, considering that an IPR is a lose-or-draw proposition for any patent holder, and that Orange Book-listed patents are so valuable to NDA holders, this may come as little comfort to the community.  Instead, anything that disrupts the balance struck by Hatch-Waxman is not going to be seen as favorable, no matter how the actual numbers have been borne out.

  • By Kevin E. Noonan

    Senate SealIn a development that could moot (once and for all) the controversy over tribal sovereign immunity occasioned by the St. Regis Mohawk Tribe's ownership of patents relating to Allergan's Restasis formulation for treating disorders of the eye, a group of Senators including Tom Cotton (R-AK), Claire McCaskill (D-MO), Pat Toomey (R-PA), Joni Ernst (R-IA), and David Perdue (R-GA) introduced a bill to broadly abrogate assertion of tribal sovereign immunity in any patent-related proceeding.  The bill, entitled the Preserving Access to Cost Effective Drugs (PACED) Act, provides that tribal sovereign immunity cannot be asserted:

    • In derivation proceedings under 35 U.S.C. § 135 and judicial review of PTAB decisions thereunder;

    • In reexamination proceedings under 35 U.S.C. § 305 and both administrative and judicial review of PTAB decisions thereunder;

    • In inter partes review proceedings under 35 U.S.C. § 316 and judicial review of PTAB decisions thereunder;

    • In post-grant review proceedings under 35 U.S.C. § 326 and judicial review of PTAB decisions thereunder; or

    • In exclusion proceedings under 19 U.S.C. § 1337 and judicial review of International Trade Commission decisions thereunder.

    The bill also expands the abrogation of sovereign immunity under 35 U.S.C. § 296 to include Indian tribes and specifically to include biosimilars under 42 U.S.C. § 262.  Each of these provisions is expressly limited by the proviso that abrogation "shall apply only to the extent permitted under the 11th amendment to the Constitution of the United States."

    Curiously, when the patent owner is a foreign state, the bill gives the Patent Trial and Appeal Board the power to determine whether the state is immune from PTAB jurisdiction, applying the principles set forth in 28 U.S.C. Chapter 97 "as if the Patent Trial and Appeal Board were a court of the United States," blurring anew the lines between Article I and Article III courts that has produced a certain amount of mischief in the implementation of the Leahy-Smith America Invents Act.

    Statements from the Senators illustrate the political motivations behind the bill:  the belief that the assignment and license arrangement between Allergan and the tribe was a sham (despite the PTAB's strenuous avoidance of that conclusion) and that such arrangements are a misuse of the patent system that only serves to increase drug prices (or, more accurately, delay generic competition that could decrease drug prices):

    • Senator Cotton:  "It's far past time that we crack down on patent abuse, which is raising costs for our seniors.  This bill will make sure unscrupulous patent holders can't game the system and block their competitors from entering the market.  That'll go a long way to help seniors get the drugs they need,"

    • Senator McCaskill:  "We watched a company brazenly try to exploit a potential legal loophole to game the system in an effort to protect their bottom line-and keep Missourians from access to cheaper generic drug options in the process.  That should be illegal, and our bipartisan bill would make it so by ending this astounding assertion of sovereign immunity to avoid patent review, before any other companies follow suit."

    • Senator Toomey:  "Sham transactions involving the transfer of patent ownership from a pharmaceutical company to a tribe for the sole purpose of shielding the patent from challenges are a clear abuse of our patent system and set a dangerous precedent for other consumer products.  The PACED Act will improve our patent system and protect patients and consumers from higher drug prices by eliminating this egregious loophole."

    • Senator Ernst:  "Congress cannot look the other way as some pharmaceutical companies attempt to stifle competition and prevent Americans from accessing affordable generic drugs.  Failure to act could incentivize other industries to use similar tactics to block competitors.  Through the Preserving Access to Cost Effective Drugs Act, we can speed up the entry of safe and affordable generic drugs into the market while maintaining the integrity of the U.S. patent system."

    • Senator Perdue:  "Gaming the patent system is not good for consumers or businesses.  I'm disappointed this legislation even has to be offered due to a few bad actors trying to do an end run around the U.S. Patent and Trademark Office."

    According to Senator Cotton's webpage, the following groups support the PACED Act:

    R Street, The Electronic Frontier Foundation, Engine, American Consumer Institute Center for Citizen Research, Public Knowledge, America's Health Insurance Plans (AHIP), Association for Accessible Medicines, United for Patent Reform, High Tech Inventors Alliance, Patients for Affordable Drugs Now, BlueCross BlueShield Association, Blue Shield of California.

    Insofar as Congressional authority over tribal sovereign immunity is "plenary," United States v. Lara, 541 U.S. 193, 200 (2004) ("the Constitution grants Congress broad general powers to legislate in respect to Indian tribes, powers that we have consistently described as 'plenary and exclusive'"), and in view of the Senators' politic framing of the issue both as an abuse and a cause of higher drug prices, only the seeming inability of this Congress to pass anything other than tax "reform" is likely to stop the bill from being enacted into law.  Perhaps the Supreme Court will rule IPRs unconstitutional in Oil States Energy Services v. Greene's Energy Group, or the pharmaceutical industry or Native American tribes can arrange matters to have naysayers be the last group to speak with Mr. Trump before he is called upon to veto the bill.  Otherwise it is likely that this particular procedural gambit has run its course.

  • By Sophie Blake* —

    The Enlarged Board of Appeal has now released its written decision in respect of G 1/16 (T 0437/14).  This decision resolves the question regarding which standard is to be applied to determine whether an "undisclosed disclaimer" in a patent claim introduces added subject-matter (that is, it contravenes Article 123(2) EPC).

    Previously G 1/03 and G 2/10 have both addressed issues regarding added subject-matter of disclaimers; this is therefore the third Enlarged Board of Appeal decision to be issued in just over a decade on this subject, which perhaps gives an indication of how contentious an issue the allowability of introducing disclaimers into patent claims is seen to be at the EPO.

    Background — undisclosed v disclosed disclaimers

    In general, patent claims typically define the subject-matter for which protection is sought in terms of "positive" technical features of the claimed invention; meaning those technical features that define the elements and characteristics of the claimed subject-matter.

    In contrast, a "disclaimer" was defined in G 1/03 as meaning an amendment to a claim resulting in the incorporation of a "negative" technical feature, typically excluding from a generally defined subject-matter specific embodiments or areas.

    For example, a claim may define its subject-matter by the following positive features:
    "A composition comprising a metal".

    However, it is also possible to define the claimed subject-matter in terms of "negative features"; for example, by introducing the feature that "the metal is not tin".  This sort of amendment can be illustrated as shown below:

    Image
    This is known as a disclaimer since what is left in the claim is less than that before the introduction of the negative feature.

    An undisclosed disclaimer refers to a disclaimer which is not disclosed in the application as filed, and nor is there any disclosure of the subject-matter excluded by it in the as-filed application; it is a disclaimer that excludes subject-matter that is not specifically mentioned in the application as filed.  Using the above example of "metal – tin", this would be an undisclosed disclaimer in the case where there is simply no mention of tin anywhere in the application as filed.

    In contrast, a disclosed disclaimer refers to a disclaimer which may not itself have been disclosed in the application as filed, but the subject-matter excluded by it is disclosed in the application as filed; it is a disclaimer that excludes subject-matter that is specifically mentioned (disclosed) in the application as filed, such as in an embodiment or example.  Again, using the above example of "metal – tin", a situation in which there is an example in the application as filed of the metal being tin would constitute this disclaimer being a disclosed disclaimer.

    G 1/03 – Allowability of undisclosed disclaimers under Article 123(2) EPC

    G 1/03 first dealt with the question of allowability under Article 123(2) EPC of undisclosed disclaimers.  In G 1/03, the Enlarged Board of Appeal held that an amendment to a claim by the introduction of a disclaimer may not be refused under Article 123(2) EPC for the sole reason that neither the disclaimer, nor the subject-matter excluded by it from the scope of the claim, have a basis in the application as filed.  However, such an undisclosed disclaimer is only allowable in certain, limited circumstances; namely, in order to:

    1.  Restore novelty against art under Article 54(3) EPC;

    2.  Restore novelty over an accidental anticipation; or

    3.  Disclaim subject-matter that is excluded from patentability for non-technical reasons under Articles 52 to 57 EPC.

    It was thus clear that undisclosed disclaimers could only be introduced if the limitation does not contribute to the invention — it must not become relevant for assessment of inventive step or sufficiency.  Furthermore, it was held that a disclaimer may only serve the purpose for which it is intended and nothing more; meaning it cannot disclaim more than is necessary to restore novelty or disclaim the non-technical subject-matter.

    G 2/10 – Allowability of disclosed disclaimers under Article 123(2) EPC

    Several years later, G 2/10 addressed a different question of whether a disclaimer infringes Article 123(2) EPC if its subject-matter was disclosed as an embodiment of the invention in the application as filed.  In other words, G 2/10 was concerned with the question of allowability of disclosed disclaimers.

    In G 2/10, the Enlarged Board of Appeal held that an amendment to a claim by the introduction of a disclosed disclaimer infringes Article 123(2) EPC if the subject-matter remaining in the claim after the introduction of the disclaimer is not, be it explicitly or implicitly, directly and unambiguously derivable from the application as filed.  This therefore confirmed that the application of the "gold standard" for assessing added matter (what the skilled person would directly and unambiguously derive from the application as filed) of disclosed disclaimers.  A number of commentators have considered that this was seemingly in conflict with the decision in G 1/03.  There followed a divergence in applicability of G 2/10 to undisclosed disclaimers:  in a number of decisions, Boards applied the gold standard test of G 2/10 to undisclosed disclaimers in addition to the criteria set out in G 1/03, whilst in some cases the allowability was primarily assessed on the basis of the gold standard alone.

    The question of which standard should be applied for undisclosed disclaimers was therefore referred to the Enlarged Board for consideration in G 1/16.

    G 1/16 decision

    In G 1/16, the Enlarged Board has confirmed that the criteria set out in G 1/03 are to be applied when considering whether a claim amended by the introduction of an undisclosed disclaimer is allowable under Article 123(2) EPC.  The gold standard test of G 2/10 is not the relevant test for examining whether an undisclosed disclaimer complies with Article 123(2) EPC

    Reasoning

    Fundamental to the Enlarged Board of Appeal's decision was the inherent conceptual differences which exist between disclosed and undisclosed disclaimers.  Indeed, the Enlarged Board of Appeal noted that, by virtue of what an undisclosed disclaimer is, when neither the disclaimer itself nor the subject-matter excluded by it is disclosed in the application as filed, it automatically follows that the subject-matter remaining in the claim after the introduction of such an undisclosed disclaimer can hardly have been considered to be derivable from the application as filed.  The Enlarged Board of Appeal held that:

    It follows from the above that the choice of the proper test . . . is determined by the fundamental distinction between disclosed and undisclosed disclaimers.  That distinction necessitates providing for each of the two classes of disclaimer a single specific test for assessing whether the introduction of a given disclaimer is in compliance with Article 123(2) EPC.  For undisclosed disclaimers, the proper test is whether the criteria of G 1/03 are fulfilled, and for disclosed disclaimers the proper test is the gold standard disclosure test of G 2/10.

    In arriving at this decision, the Enlarged Board of Appeal also noted that the idea underlying Article 123(2) EPC is that the applicant should not be given an unwarranted advantage, and precludes a new technical contribution being added by an amendment.  G 1/03 was considered not to be in contradiction with this premise.

    Conclusion

    This decision has clarified that the door is not being shut entirely on the use of undisclosed disclaimers.  This provides some relief as it will therefore still be possible for applicants to introduce undisclosed disclaimers where necessary in order to exclude prior art that is either an accidental anticipation or post-published, or in order to exclude non-technical features.

    Of course, it still needs to be borne in mind that the criteria for allowability of undisclosed disclaimers under Article 123(2) EPC is very restricted.  Applicants should therefore continue to draft applications with sufficient fall-back positions, preferably in terms of positive features, that allow for limitations to be made during prosecution without needing to rely on the introduction of such undisclosed disclaimers.  The introduction of such disclaimers should be relied on sparingly.

    * Ms. Blake is a patent attorney with D Young & Co

    This article was reprinted with permission from D Young & Co.

  • By Kevin E. Noonan

    Saint Regis Mohawk TribeThe St. Regis Mohawk Tribe and Allergan filed a joint motion late last week before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB), arguing that its Notice of Appeal divested the Board of jurisdiction over the inter partes review proceedings related to the Tribe's patents obtained by assignment by Allergan, and thus that the Board can no longer proceed to Final Written Decision in any of these IPRs.  In the alternative, the Tribe argues that the Board should suspend the IPRs under 37 C.F.R. § 42.5(a) pending Federal Circuit review, because "the issues raised in [these proceedings] are important matters of first impression not contemplated by the statutory scheme."

    AllerganOn the divestiture argument, the Tribe's brief in support of its Motion first establishes its right to immediate appellate review under the collateral order doctrine, citing Osage Tribal Council ex rel. Osage Tribe of Indians v. U.S. Dep't of Labor, 187 F.3d 1174 (10th Cir. 1999); Wisconsin v. Ho-Chunk Nation, 512 F.3d 921, 928 (7th Cir. 2008); and In re Board of Regents of The Univ. of Tex. Sys., 435 F. App'x 945, 947-48 (Fed. Cir. 2011), all to the effect that denial of tribal sovereign immunity in an administrative agency proceeding is immediately appealable.  The Tribe cites the Supreme Court standard, that interlocutory review of an order is immediately reviewable if it "conclusively determine[s] the disputed question, resolve[s] an important issue completely separate from the merits of the action, and [is] effectively unreviewable on appeal from a final judgment," citing Justice Brennan's concurring opinion in Mitchell v. Forsyth, 472 U.S. 511, 543 (1985).  The Tribe is entitled to having immunity decided before final judgment, according to the Tribe's interpretation of Supreme Court precedent, because if properly immune, the Tribe should not be subjected to judgment at all.  It is "immunity from suit rather than a mere defense to liability[]" that is at issue, and "[the immunity] is effectively lost if a case is erroneously permitted to go to trial," according to the brief, citing Burlington N. & Santa Fe Ry Co. v. Vaughn, 509 F.3d 1085, 1090 (9th Cir. 2007) (emphasis in original).

    The brief counters Petitioners' position that, inter alia, precedent related to immunity is inapposite because an IPR is not a trial but rather a specialized administrative agency proceeding by contending that an IPR is an "adjudicatory process" and the Tribe is asserting absolute immunity from being subjected to it.  Also, sovereign immunity is a jurisdictional issue that can be raised at any time, according to the brief, and the Tribe asserts that it raised it "at its first opportunity to do so – the day it acquired the patents."

    As a consequence, the Tribe argues that its appeal divests the Board from jurisdiction over the IPR unless and until the Federal Circuit decides the appeal, citing Forsyth and Apostol v. Gallio, 870 F.2d 1335, 1338 (7th Cir. 1989), to the effect that "[t]he justification for the interlocutory appeal is that the trial destroys rights created by the immunity."  The brief also cites precedent from several Circuit Courts of Appeal as well as the Supreme Court that a notice of appeal divests a district court of jurisdiction.  Closer to home, the brief cites Federal Circuit (In re Graves, 69 F.3d 1147, 1149 (Fed. Cir. 1995)) and Board (Smart Microwave Sensor GmbH, IPR2016-00488, 2017 WL 3669083, at *1 (Aug. 24, 2017)) cases on this point ("The general rule is that the Board is divested of jurisdiction when either party files a notice of appeal to the Federal Circuit.").  The brief also sets forth the equitable basis for its position:  "If this Board went forward despite the appeal, the Tribe will be forced to choose between appearing before the Board, thereby losing its immunity, or risk losing its substantial property rights in absentia."  Hardly seems fair.  And the argument that the Tribe's interests can be adequately represented by Allergan begs the question, because whether or not that is the case is "'inextricably tied' to the question of immunity" that is the subject of the Tribe's appeal to the Federal Circuit.

    The brief then ups the ante, by contending that the Board is without authority to ignore these procedural requirements or to have determined that Allergan could adequately represent the Tribe's interests in the IPR:

    The Tribe will further argue that PTAB has no authority to create equitable or common law rules to facilitate the exercise of its Congressional mandate through its written decisions and orders in IPRs; only the Director has rulemaking authority under the AIA. 35 U.S.C. § 316(a); Am. Library Ass'n v. FCC, 406 F.3d 689, 698 (D.C. Cir. 2005) (noting agencies have no constitutional or common law authority, only authority granted by Congress).  PTAB has no implied authority to create ad hoc rules and new forms of PTAB standing to facilitate what it perceives to be its mission.  The Supreme Court has held "[r]egardless of how serious the problem an administrative agency seeks to address, [an agency] may not exercise its authority in a manner that is inconsistent with the administrative structure that Congress enacted into law."  Food & Drug Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 125 (2000) (internal quotation omitted).  Doing so "would deal a severe blow to the Constitution's separation of powers."  Utility Air Regulatory Group v. E.P.A., 134 S. Ct. 2427, 2446 (2014).  Thus, on appeal, the Tribe will argue that the Board erred when it deemed Allergan the "effective owner" in order to avoid the Tribe's immunity as an impediment to Board jurisdiction.

    In the only portion of the brief resembling a carrot or peace offering, the Tribe argues in the alternative that there is a mechanism for the Board to suspend proceedings in anticipation of the Federal Circuit's ultimate ruling on the tribal sovereign immunity question.  Under 37 C.F.R. § 42.5(a), the Board is empowered to "determine proper course of conduct in a proceeding for any situation not specifically covered" and to "set times by order."  Sovereign immunity is just such an issue that is "not specifically covered" or anticipated by the statute, and thus the Tribe argues in its brief that it is entitled to the "extraordinary relief" contemplated by Rule 42.1(a).  In addition, the brief reminds the Board that the statute already permits the time limit for a Final Written Decision to be extended by six months and (as here) in cases of joinder, citing 35 U.S.C. § 316(a)(11).  The brief mentions that failure to adhere to the statutory time limit is without penalty, and then recites three "distinct and important issues" raised in this case that justify resorting to the extension of time provisions of the statute:

    • Tribal immunity from suit before the PTAB;
    • The "schism" between the Board's decision regarding tribal immunity and State sovereign immunity in Ericsson Inc., et al v. Regents of the Univ. of Minn., IPR2017-01186, Paper 14 at 4 (Dec. 19, 2017); and
    • The panel split over jurisdiction as applied to the tribe in this case and to state actors (universities) in Covidien LP v. Univ. of Fla. Research Found. Inc., IPR2016-01274, Paper 21 at 19 (Jan. 25 2017); Neochord, Inc. v. Univ. of Md. et al, Case IPR2016-00208, Paper 28 at 6-7 (May 23, 2017); Reactive Surfaces Ltd, LLP v. Toyota Motor Corp., Case IPR2016-01914, Paper 36 at 7-8 (July 13, 2017); Minnesota Order at 4-6.

    The brief ends with a warning:  "If necessary, the Tribe and Allergan intend to seek emergency relief from the Federal Circuit no later than March 16, 2018."

    In addition to the legal issues addressed in the Tribe's brief, another question arises:  by filing this motion is the Tribe (or at least their counsel) playing with fire?  Recall that after filing a motion for discovery regarding, inter alia, whether the PTAB would "stack the panel" by adding members to "ensure consistency with Office policies" (see "Skeptical St. Regis Mohawk Tribe Requests Discovery Regarding Panel Selection Circumstances"), the PTAB in a sharply-worded Order precluded the tribe or their counsel from filing any additional papers in the IPR without express authorization from the Board (see "The PTAB Strikes Back — Issues Order Prohibiting St. Regis Mohawk Tribe from Filing Any Additional Papers in IPR").  That Order also included the following warning:

    As a final note, we caution counsel for the Tribe that failure to comply with an applicable rule or order, abuse of discovery, and abuse of process are all grounds for sanctions.  37 C.F.R. § 42.12(a)(1), (5), (6).  We strongly advise counsel for the Tribe to review our rules and caution that any further actions that demonstrate a disregard for our process will not be tolerated.  See 37 C.F.R. § 42.12(b).

    This prohibition does not apply to the Notice of Appeal, of course, filed at the end of last month (see "St. Regis Mohawk Tribe and Allergan Appeal Denial of Motion to Dismiss on Sovereign Immunity Grounds").  But this Motion once again contains a flavor of mistrust, that the Board will attempt to forestall the Tribe's appeal by mooting it and issuing a Final Written Decision before the Federal Circuit can decide the issue.  Perhaps provoking the kind of response from the Board that the Tribe did with its earlier discovery motion is intentional, the aim being to use any similar response to support a motion to the Federal Circuit for a writ precluding the Board from acting peremptorily.  It is clear that the Tribe and its counsel are willing to use the kind of zealous tactics common in district court litigation against the Board, and that the Board is not used to and does not appreciate being treated in this fashion.  But the stakes here, for both Allergan and the Tribe (and all tribes; see "Amicus Briefs Filed in Mohawk Tribe's Motion to Dismiss IPRs") are apparently sufficiently high to justify ruffling a few Administrative Patent Law judge's feathers in the process and the Tribe and its counsel show no reluctance to ruffle.

  • By Kevin E. Noonan

    Federal Circuit SealThe tortured path that the Federal Circuit has taken (a path also trodden by the U.S. Patent and Trademark Office and the district courts) of applying the patent eligibility decisions under Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corp. v. CLS Bank Int'l. is illustrated in a 2-1 decision handed down by the Federal Circuit on March 8th in Exergen Corp. v. Kaz USA, Inc.  In comparing the rationales used by the District Court and the majority with the dissenting opinion, this case illuminates a fundamental issue in properly applying subject matter eligibility law that, if adopted could avoid much of the confusion and uncertainty injected into the law by the Supreme Court's recent decisions.

    The patents at issue, U.S. Patent No. 6,292,685 and U.S. Patent No. 7,787,938, were directed to body temperature detection apparatus and methods for detecting body temperature, respectively.  Representative claims are as follows:

    U.S. Patent No. 6,292,685:

    48.  A body temperature detector comprising:
        a radiation detector; and
        electronics that measure radiation from at least three readings per second of the radiation detector as a target skin surface over an artery is viewed, the artery having a relatively constant blood flow, and that process the measured radiation to provide a body temperature approximation, distinct from skin surface temperature, based on detected radiation.

    49.  The body temperature detector of claim 48 wherein the artery is a temporal artery.

    U.S. Patent No. 7,787,938:

    14.  A method of detecting human body temperature comprising making at least three radiation readings per second while moving a radiation detector to scan across a region of skin over an artery to electronically determine a body temperature approximation, distinct from skin surface temperature.

    24.  The method of claim 14 wherein the artery is a temporal artery.

    The claimed detectors calculate a person's body temperature "by detecting the temperature of the forehead directly above the superficial temporal artery."  The device then calculates the body temperature by applying a "constant coefficient" to skin and ambient temperature readings.  The temperature is detected by scanning the forehead to detect a peak reading that indicates the location of the temporal artery and hence provides the most reliable temperature reading.

    Kaz sold competing temperature-sensing apparatus; two other defendants, Brooklands Inc. and Thermomedics Inc., were also sued in parallel proceedings, with the District Court consolidating the lawsuits solely for claim construction purposes.  Not dispositive here but providing an interesting counterpoint to the decision in this case, certain claims of both the '685 and '938 patents were held to be invalid on the basis of lack of subject matter eligibility under § 101 in these other lawsuits.  In this case, a jury found the patents to be infringed and not invalid and assessed damages (in a total amount in excess of $15 million).  The District Court denied Kaz's summary judgment motions and motions for JMOL that the claims were invalid under § 101, as well as that the '685 patent was not infringed and for a new trial on damages, and granted Kaz's summary judgment motion of no willful infringement.  Both parties appealed the adverse judgments against them.

    The Federal Circuit affirmed the decision on § 101, reversed denial of JMOL on infringement of the '685 patent, vacated judgment for damages as a result of its decision on '685 patent infringement, and remanded for the District Court to recalculate damages, in a decision by Judge Moore joined by Judge Bryson; Judge Hughes dissented.

    The majority set forth the now canonical two-prong test for subject matter eligibility under Mayo and Alice: the claims need to be "directed to" a law of nature, natural phenomenon or abstract idea, and there must be "something more" amounting to an "inventive concept" that is not merely "routine, conventional, and well-understood" in the prior art.  Here, the majority spends little time on the first prong, accepting without comment that the claimed invention is dependent on the "natural law" that body temperature can be measured from skin temperature at the forehead.  The District Court had relied on Diamond v. Diehr, 450 U.S. 175 (1981), for the principle that claims can recite "additional steps" that "transformed the underlying natural laws into inventive methods and useful devices that noninvasively and accurately detect human body temperature."  These steps, which included "(1) moving while laterally scanning ('685 patent claims 7, 14, and 17; '938 patent claims 17, 24, 33, 60, and 66); (2) obtaining a peak temperature reading ('685 patent claim 7; '938 patent claims 60 and 66); and (3) obtaining at least three readings per second ('938 patent claims 17, 24, 39, 40, 46, and 49)" were known in the prior art but that was not enough.  According to the District Court "simply being known in the art did not suffice to establish that the subject matter was not eligible for patenting" because "a new combination of steps in a process may be patentable even though all the constituents of the combination were well known and in common use before the combination was made," citing Diehr.  The distinction (and in some ways the distinction missing from much of § 101 jurisprudence post-Mayo) is that these methods were used for a different purpose in the prior art, in this case detecting "hot spots" indicative of tumors, fractures, or other injuries (and in at least some testimony, used in horses not humans).  In addition, the invention here newly provided a "calculated coefficient for translating measurements taken at the forehead into core body temperature readings" which was not routine, well understood or conventional in the prior art.

    The majority considered these findings, regarding what was routine, conventional and well understood in the prior art, to be findings of fact, and thus entitled to the deferential "clear error" standard of review.  The opinion explains that, although the question of subject matter eligibility is one of law it is (or at least can be; the opinion is careful to state that it isn't always) reliant on underlying facts, analogizing this question to indefiniteness, enablement, and non-obviousness.  To illustrate this point, the opinion goes on to say that "[s]omething is not well-understood, routine, and conventional merely because it is disclosed in a prior art reference," setting forth the hoary precedent of In re Hall wherein although the presence of a "thesis written in German and located in a German university library" was sufficient to qualify as prior art because it was available to the public, it would not without more be enough to satisfy the requirement that something be routine, conventional and well understood in the prior art.  The opinion further distinguishes both Mayo and Ariosa v. Sequenom on the basis that the methods recited in those claims were undisputedly routine, conventional and well understood.

    The opinion states that "[t]his case is different," and it is informative to consider the basis for this determination:

    Following years and millions of dollars of testing and development, the inventor determined for the first time the coefficient representing the relationship between temporal-arterial temperature and core body temperature and incorporated that discovery into an unconventional method of temperature measurement.  As a result, the method is patent eligible, similar to the method of curing rubber held eligible in Diehr.

    Finally, the panel refused to consider Kaz's arguments that it had a Seventh Amendment right to have patent eligibility decided by a jury (saying that is "a question which awaits more in-depth development and briefing than the limited discussion in this case"), based on at least three instances ("before, during, and after trial") where Kaz waived the issue.

    As to the other questions before the Court, the panel decided that the claims of the '685 patent were not infringed because the accused devices reported the "oral equivalent" temperature rather than the "temperature of the body beneath the forehead" as required by the claims.  Accordingly, the panel vacated the damages below (while affirming the methodology regarding reasonable royalty and lost profits calculations) and remanded for recalculation based on non-infringement of the '685 patent claims.  And the panel majority also found that the District Court's grant of Kaz's summary judgment motion that infringement was not willful was not an abuse of discretion and not inconsistent with the Supreme Court's decision in Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923, 1934 (2016), setting forth the proper standard to applying the enhanced damages provisions of 35 U.S.C. § 284.

    Judge Hughes' dissent was based on his view that the District Court committed clear error in not deciding that the undisputed presence in the prior art of apparatus for detecting "hot spots" was enough for the claimed methods to be routine, conventional and well understood.  According to Judge Hughes, a hallmark of a patent-ineligible claim is one that "begins and ends" with a non-eligible judicial exception, citing Ariosa.  He perceives that this is the case here, because the claim "begins" with the ineligible law of nature (that body temperature can be detected at the forehead due to the presence of the temporal artery), and ends with a determination of body temperature.  (On this point, the analysis must be more detailed than that, otherwise any claim for a method of doing something that arises in the natural world would be per se ineligible.)  As to the equations developed at such a cost that impressed the District Court and the panel majority, Judge Hughes sees these as merely deriving from the "the principle that heat generated by a person's body flows throughout the body and, eventually, into the environment" and that "[t]he prior art recognized long ago that this principle enabled the calculation of core body temperature from skin and air temperature measurements."

    It is in Judge Hughes' discussion of whether the invention provides an inventive concept that is not well understood, routine, and conventional that the competing views of the eligibility issue are properly set out.  Judge Hughes maintains that:

    [A]side from its use of a newly discovered heat balance coefficient, Exergen's claimed invention amounts to nothing more than using a preexisting temperature detector to take a conventional and routine measurement of forehead skin temperature.  Absent the patent-ineligible law of nature, the claimed invention consists entirely of elements already combined by the prior art.  Thus, the claimed combination of elements lacks an inventive concept because the combination was well-understood, routine and conventional at the time of invention.

    The District Court's error was that it:

    [N]ever found that the combination of taking multiple measurements while scanning laterally across the forehead to determine peak temperature was not well-understood, routine, and conventional.  It only found that there was "no evidence . . . that these steps were 'well-understood, routine, [or] conventional[ly]' used to detect arterial temperature beneath the skin." [alterations in original] (emphasis added).  Rather than finding that the claim elements were not routine or conventional, the district court focused on whether those elements were routinely or conventionally used for the purpose of calculating core body temperature.  It differentiated the claimed invention from the prior art solely on the basis that the claimed invention "solve[s] a different problem."

    Judge Hughes properly notes that the Federal Circuit "rejected identical reasoning in Ariosa," which is not to say that the Court's reasoning in that case was sound, as illustrated by Judge Hughes' synopsis of the Ariosa decision:

    Although the claimed methods solved a novel problem, using conventional techniques for a new purpose did not supply an inventive concept that amounted to significantly more than the natural phenomenon to which the claims were directed.

    As applied to this case:

    Despite recognizing that temperature detectors identical to the claimed invention already existed for other purposes, the district court reasoned that these prior detectors never used forehead skin temperature measurements to calculate core body temperature.  Like in Ariosa, this reasoning implicitly relies upon the relationship between forehead skin temperature and core body temperature to supply an inventive concept.  Although the invention calculates core body temperature from forehead temperature, those calculations merely reflect the natural relationship between forehead and core body temperatures.  Accordingly, the district court clearly erred by finding an inventive concept based on the asserted claims' use of well-understood, routine, and conventional temperature- measuring techniques for this new purpose.

    This reasoning sets forth exactly what is wrong with how the USPTO (sometimes), the district courts (too often), and the Federal Circuit (much too often in view of their mandate and purported expertise in patent law) have applied the Supreme Court's Mayo/Alice jurisprudence.  This application, wherein discovery of a new phenomenon and using conventional means to detect it, when such detection is not possible in the prior art, extends patent ineligibility further than the Court has indicated it needs to go.  It is one thing to take conventional activity and prevent it from being subject to patent exclusivity without the elusive "something more" and quite another to preclude beneficial method claims to detect previously unknown phenomena unless a new method for detecting is also provided.

    Perhaps Judge Hughes points to a way in which the analysis can be refined to avoid this consequence, focusing on how the first prong of the Mayo/Alice test is applied:

    I am not suggesting that considering the integration of a law of nature into the claimed invention is improper at every stage of § 101 analysis.  Indeed, step one requires us to examine the claims holistically in order to determine whether they are directed to an ineligible concept.  See Enfish, LLC v. Microsoft Corp., 822 F.3d 1327, 1335 (Fed. Cir. 2016) ("Rather, the 'directed to' inquiry applies a stage-one filter to claims, considered in light of the specification, based on whether 'their character as a whole is directed to excluded subject matter.'" (quoting Internet Patents Corp. v. Active Network, Inc., 790 F.3d 1343, 1346 (Fed.Cir.2015))).  Upon reaching step two, however, we focus more narrowly on the claim elements other than the invention's use of the ineligible concept to which it is directed.  Accordingly, the majority's analysis of the claims as a whole belongs at step one.

    But of course, that hope is somewhat dashed in the next sentence:

    At either step, however, for the reasons discussed above, a claimed invention's unconventionality, by itself, is not sufficient to render the claim patent eligible.

    For a statutory regime purportedly aimed at innovation, it is reasonable to ask, "why not"?

    Exergen Corp. v. Kaz USA, Inc. (Fed. Cir. 2018)
    Nonprecedential disposition
    Panel: Circuit Judges Moore, Bryson, and Hughes
    Opinion by Circuit Judge Moore; dissenting opinion by Circuit Judge Hughes

  • CalendarMarch 13, 2018 – "Top Stories at the PTAB: What You Need to Know" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    March 13, 2018 – "Subject Matter Eligibility: Guidance & Examination Resources" (U.S. Patent and Trademark Office) – 12:00 to 1:00 pm (ET)

    March 13, 2018 – "Apportionment in Patent Damages: What You Need to Know and Do" (The Knowledge Group) – 12:00 to 1:00 pm (ET)

    March 14, 2018 – Patent Litigation Seminar (New Jersey Intellectual Property Law Association) – 12:00 to 5:00 pm, Iselin, NJ

    March 15, 2018 – "On Sale and Public Use Bars to Patentability: Minimizing the Risk of Patent Ineligibility or Invalidation" (Strafford) – 1:00 to 2:30 pm (EDT)

    March 15, 2018 – 2018 Business Methods Partnership Meeting (U.S. Patent and Trademark Office) – 1:00 to 4:00 pm (ET), Alexandria, VA

    March 15, 2018 – Patent Administrative Law Conference (American University, the Federal Circuit Bar Association, and Unified Patents) – 12:00 to 6:00 pm (EDT), Washington, DC

    March 15, 2018 – "Waymo v. Uber: DTSA Test Tube" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    March 20, 2018 – "How to Secure and Exploit Patents for Combination Therapies" (J A Kemp) – 3:30 to 4:30 pm (GMT)

    March 20, 2018 – Technology Center 1700 Customer Partnership meeting (U.S. Patent and Trademark Office) – 12:00 to 2:00 pm (ET), Alexandria, VA

    March 20, 2018 – "USPTO Examiner Interview Strategies: Preparing for and Conducting Interviews to Advance Patent Prosecution" (Strafford) – 1:00 to 2:30 pm (EDT)

    March 22, 2018 – Biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting (U.S. Patent and Trademark Office) – Alexandria, VA

    March 28, 2018 – "Patent Infringement: Structuring Opinions of Counsel — Leveraging Opinion Letters to Reduce the Risks of Liability and Enhanced Damages" (Strafford) – 1:00 to 2:30 pm (EDT)

    March 29, 2018 – "The Evolving Scope of IPR Estoppel" (Federal Circuit Bar Association) – 1:00 pm to 2:00 pm (EST), Washington, DC

    April 5, 2018 – "Paragraph IV Litigation and IPRs — Interplay Between Paragraph IV Litigation and IPRs, Multiple Generic Challengers, Key Issues in IPRs" (Strafford) – 1:00 to 2:30 pm (EDT)

  • USPTO Building FacadeThe U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on March 22, 2018 at the USPTO Headquarters (Alexandria, VA).  The agenda for the meeting is as follows:

    • Welcoming and Opening Remarks (10:00 – 10:10 am EDT) — Daniel Sullivan and Andrew Wang, Directors, TC1600, USPTO

    • Obviousness of Biologics: Identifying the Biggest Challenges (10:10 – 11:00 am) — Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum LLP

    • 103 KSR Rationales (11:00 – 11:50 am) — Lora Driscoll, QAS, TC1600, USPTO

    • Lunch (11:50 am – 12:50 pm)

    • 112(f)-New Form Paragraphs (12:50 – 1:40 pm) — Marjorie Moran, QAS, and Heather Calamita, SPE, TC1600, USPTO

    • Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements (1:40 – 2:40 pm) — Amjad Abraham, SPE, and Shubo (Joe) Zhou, SPE, TC1600, USPTO

    • Break (2:40 – 3:00 pm)

    • Accidental Infringement: the need for additional limitations in plant utility claims directed to chemical profiles or cultivars (3:00 – 3:50 pm) — Reggie Gaudino, Chief Science Officer, Steep Hill Labs, Inc.

    • Closing Remarks (3:50 – 4:00 pm) – Directors, TC1600, USPTO

    Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.